TDMS No. 99028 - 05 Test Type: CHRONIC Route: SKIN APPLICATION Species/Strain: RATS/F 344	P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a) bis(2-Chloroethoxy)methane CAS Number: 111-91-1	Date Report Reqsted: 11/12/2007 Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT
	F1_R2	
C Number:	C99028	
Lock Date:	07/12/2005	
Cage Range:	ALL	
Date Range:	ALL	
Reasons For Removal:	ALL	

Removal Date Range:

Treatment Groups:

**TDMSE Version:** 

ALL

1.9.1

Include ALL

**TDMS No.** 99028 - 05 **Test Type:** CHRONIC

Route: SKIN APPLICATION Species/Strain: RATS/F 344

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Date Report Reqsted: 11/12/2007 Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	75 MG/KG	150 MG/KG	300 MG/KG	
Disposition Summary					
Animals Initially in Study	50	50	50	50	
Early Deaths Moribund Sacrifice	21	17	31	20	
Natural Death	8	4	5	20 6	
Survivors	-		-	-	
Moribund Sacrifice		1			
Terminal Sacrifice	21	28	14	24	
Animals Examined Microscopically	50	50	50	50	
ALIMENTARY SYSTEM					
Esophagus	(50)	(50)	(50)	(50)	
Inflammation	( )	1 (2%)		~ /	
Ulcer	(10)	1 (2%)	(50)	(50)	
Intestine Large, Cecum Edema	(49) 1 (2%)	(50)	(50)	(50)	
Inflammation	1 (2%)				
Parasite Metazoan	1 (270)	1 (2%)			
Intestine Large, Colon	(50)	(50)	(50)	(50)	
Parasite Metazoan		2 (4%)			
Intestine Large, Rectum	(50)	(50)	(50)	(50)	
Parasite Metazoan Intestine Small, Duodenum	11 (22%)	5 (10%)	7 (14%)	7 (14%)	
Inflammation	(50)	(50)	(50)	(50) 1 (2%)	
Ulcer		1 (2%)		1 (2%)	
Epithelium, Hyperplasia		1 (2%)		. (_,,,,	
Intestine Small, Ileum	(50)	(50)	(50)	(50)	
Inflammation	/= - \	1 (2%)	()	()	
Intestine Small, Jejunum	(50)	(50)	(50)	(50)	
Liver	(50) 1 (2%)	(50) 7 (14%)	(50) 3 (6%)	(50) 6 (12%)	
Angiectasis Basophilic Focus	19 (38%)	19 (38%)	16 (32%)	19 (38%)	
Clear Cell Focus	22 (44%)	24 (48%)	14 (28%)	22 (44%)	
Degeneration, Cystic	6 (12%)	5 (10%)	10 (20%)	15 (30%)	
Eosinophilic Focus	10 (20%)	15 (30%)	8 (16%)	11 (22%)	
Fatty Change	19 (38%)	20 (40%)	16 (32%)	20 (40%)	
Fibrosis	39 (78%)	25 (50%)	23 (46%)	31 (62%)	
Hematopoietic Cell Proliferation Hepatodiaphragmatic Nodule	2 (4%) 4 (8%)	E (100/)	6 (100/)	9 (18%)	
Inflammation	4 (8%) 32 (64%)	5 (10%) 38 (76%)	6 (12%) 33 (66%)	9 (18%) 41 (82%)	
Mixed Cell Focus	4 (8%)	10 (20%)	8 (16%)	3 (6%)	

# Test Type: CHRONIC Route: SKIN APPLICATION

Species/Strain: RATS/F 344

# P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

bis(2-Chloroethoxy)methane

### CAS Number: 111-91-1

Date Report Reqsted: 11/12/2007 Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	75 MG/KG	150 MG/KG	300 MG/KG	
Necrosis Thrombosis	4 (8%)	2 (4%)	5 (10%) 2 (4%)	3 (6%)	
Bile Duct, Cyst		1 (2%)	2 (4%)	1 (2%)	
Bile Duct, Hyperplasia	46 (92%)	46 (92%)	44 (88%)	47 (94%)	
Centrilobular, Necrosis	1 (2%)	4 (8%)	8 (16%)	4 (8%)	
Mesentery	(10)	(10)	(9)	(9)	
Accessory Spleen	1 (10%)	(10)	(0)	(0)	
Fat, Necrosis	8 (80%)	9 (90%)	8 (89%)	8 (89%)	
Oral Mucosa	(2)	(0)	(0)	(0)	
Inflammation, Granulomatous	1 (50%)	(-)	(-)	(-)	
Gingival, Cyst	2 (100%)				
Pancreas	(50)	(50)	(50)	(50)	
Acinus, Atrophy	17 (34%)	21 (42%)	17 (34%)	17 (34%)	
Acinus, Hyperplasia	2 (4%)	1 (2%)	1 (2%)	3 (6%)	
Duct, Cyst	11 (22%)	5 (10%)	4 (8%)	5 (Ì0%́)	
Salivary Glands	(50)	(50)	(50)	(50)	
Stomach, Forestomach	(50)	(50)	(50)	(50)	
Inflammation		2 (4%)	6 (12%)	10 (20%)	
Ulcer		2 (4%)	2 (4%)	7 (14%)	
Epithelium, Hyperplasia	2 (4%)	1 (2%)	1 (2%)	1 (2%)	
Stomach, Glandular	(50)	(50)	(50)	(50)	
Ectopic Tissue	1 (2%)				
Inflammation	1 (2%)	2 (4%)	1 (2%)		
Mineralization		1 (2%)			
Ulcer	1 (2%)	1 (2%)	1 (2%)		
RDIOVASCULAR SYSTEM					
Heart	(50)	(50)	(50)	(50)	
Cardiomyopathy	46 (92%)	48 (96%)	45 (90%)	49 (98%)	
Fibrosis	50 (100%)	50 (100%)	49 (98%)	49 (98%)	
Inflammation, Chronic Active	1 (2%)				
Thrombosis	3 (6%)	1 (2%)	4 (8%)	3 (6%)	
Coronary Artery, Inflammation		1 (2%)			
Endothelium, Hyperplasia	1 (2%)				
Myocardium, Infiltration Cellular, Mononuclear	50 (100%)	50 (100%)	49 (98%)	50 (100%)	
Cell					
Myocardium, Necrosis	50 (100%)	50 (100%)	49 (98%)	50 (100%)	
Nyocardium, Vacuolization Cytoplasmic	50 (100%)	50 (100%)	49 (98%)	50 (100%)	
DOCRINE SYSTEM					
Adrenal Cortex	(50) 1 (2%)	(50)	(50)	(50)	

# Test Type: CHRONIC

# Route: SKIN APPLICATION

Species/Strain: RATS/F 344

### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

bis(2-Chloroethoxy)methane

### CAS Number: 111-91-1

Date Report Reqsted: 11/12/2007 Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	75 MG/KG	150 MG/KG	300 MG/KG	
Hyperplasia	16 (32%)	22 (44%)	13 (26%)	16 (32%)	
Vacuolization Cytoplasmic	33 (66%)	38 (76%)	35 (70%)	39 (78%)	
Adrenal Medulla	(50)	(50)	(50)	(50)	
Angiectasis	(33)	1 (2%)	(00)	2 (4%)	
Hemorrhage	1 (2%)	. (=,0)		= ( : / 3)	
Hyperplasia	9 (18%)	7 (14%)	8 (16%)	10 (20%)	
slets, Pancreatic	(50)	(50)	(50)	(50)	
Hyperplasia	4 (8%)	9 (18%)	11 (22%)	5 (10%)	
Parathyroid Gland	(49)	(44)	(45)	(47)	
Hyperplasia	(10)	1 (2%)	(10)	()	
Hyperplasia, Focal		()		1 (2%)	
Pituitary Gland	(49)	(50)	(50)	(50)	
Angiectasis	37 (76%)	30 (60%)	26 (52%)	32 (64%)	
Atrophy	1 (2%)		()		
Cyst	6 (12%)	6 (12%)	10 (20%)	8 (16%)	
Pars Distalis, Hyperplasia	13 (27%)	16 (32%)	12 (24%)	17 (34%)	
Thyroid Gland	(50)	(50)	(50)	(50)	
Cyst	1 (2%)	1 (2%)	1 (2%)	1 (2%)	
Inflammation	· · · /	1 (2%)			
C-cell, Hyperplasia	21 (42%)	22 (44%)	23 (46%)	14 (28%)	
Follicle, Cyst		1 (2%)	- ( /	(/	
Follicle, Hyperplasia	1 (2%)	4 (8%)	1 (2%)	2 (4%)	

### GENERAL BODY SYSTEM

None

### **GENITAL SYSTEM**

Epididymis	(50)	(50)	(50)	(50)
Granuloma Sperm	1 (2%)			
Inflammation	1 (2%)			1 (2%)
Penis	(0)	(0)	(1)	(0)
Inflammation			1 (100%)	
Preputial Gland	(50)	(50)	(50)	(50)
Cyst		3 (6%)	2 (4%)	
Hyperplasia			1 (2%)	2 (4%)
Inflammation	50 (100%)	50 (100%)	47 (94%)	49 (98%)
Duct, Ectasia			1 (2%)	
Prostate	(50)	(50)	(50)	(50)
Hyperplasia	39 (78%)	41 (82%)	39 (78%)	40 (80%)
Inflammation	44 (88%)	37 (74%)	32 (64%)	42 (84%)
Inflammation, Suppurative	1 (2%)			. ,
Seminal Vesicle	(50)	(50)	(50)	(50)

# Test Type: CHRONIC Route: SKIN APPLICATION

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Date Report Reqsted: 11/12/2007 Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	75 MG/KG	150 MG/KG	300 MG/KG	
Inflammation	2 (4%)			2 (4%)	
Testes	(50)	(50)	(50)	(50)	
Inflammation, Granulomatous Necrosis		1 (2%)	1 (2%)		
Germinal Epithelium, Atrophy	2 (4%)	1 (2%)	1 (2%)		
Germinal Epithelium, Mineralization	1 (2%)	1 (2%)	. (_,,,)	2 (4%)	
Tunic, Fibrosis		1 (2%)			
HEMATOPOIETIC SYSTEM					
Bone Marrow	(50)	(50)	(50)	(50)	
Atrophy Hyperplasia	3 (6%)	1 (2%)	4 (8%) 4 (8%)	2 (4%)	
Lymph Node	3 (6%) (4)	(0)	4 (8%) (6)	(5)	
Deep Cervical, Ectasia	( ')	(-)	1 (17%)		
Deep Cervical, Hyperplasia, Lymphoid			1 (17%)	1 (20%)	
Mediastinal, Hyperplasia, Lymphoid Lymph Node, Mesenteric	(50)	(50)	(50)	1 (20%) (50)	
Ectasia	1 (2%)	(50)	(50)	(30)	
Hyperplasia, Lymphoid				1 (2%)	
Inflammation, Chronic Active	1 (2%)	(50)	(10)	(50)	
Spleen Atrophy	(50)	(50)	(49) 3 (6%)	(50) 4 (8%)	
Fibrosis			2 (4%)	1 (2%)	
Hematopoietic Cell Proliferation	24 (48%)	25 (50%)	15 (31%)	24 (48%)	
Infarct			1 (2%)		
Stromal Hyperplasia Thymus	(49)	(50)	1 (2%) (50)	(48)	
Atrophy	45 (92%)	50 (100%)	46 (92%)	47 (98%)	
Ectopic Parathyroid Gland	1 (2%)	( )			
Ectopic Thyroid				1 (2%)	
NTEGUMENTARY SYSTEM					
Mammary Gland	(49)	(50)	(50)	(50)	
Hyperplasia	13 (27%)	10 (20%)	7 (14%)	12 (24%)	
Skin Cyst Epithelial Inclusion	(50) 1 (2%)	(50) 3 (6%)	(50)	(50)	
Edema	1 (2%)	5 (070)			
Hemorrhage	· · /	1 (2%)			
Artery, Site Of Application - Dermis,		1 (2%)			
Inflammation Control Dermis, Fibrosis			1 (2%)		
Dermis, Inflammation		1 (2%)	· (2/0)		
, ,					

## Test Type: CHRONIC Route: SKIN APPLICATION

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Date Report Reqsted: 11/12/2007 Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	75 MG/KG	150 MG/KG	300 MG/KG	
Hair Follicle, Site Of Application - Epidermis, Atrophy	1 (2%)				
Sebaceous Gland, Hyperplasia Site Of Application - Dermis, Fibrosis		1 (20/)	1 (2%)		
Site Of Application - Dermis, Inflammation	2 (4%)	1 (2%) 2 (4%)	2 (4%)		
Site Of Application - Epidermis,		1 (2%)	1 (2%)		
Hyperkeratosis Site Of Application - Epidermis, Ulcer	1 (2%)				
	. (_,,,)				
MUSCULOSKELETAL SYSTEM					
Bone	(50)	(50)	(50)	(50)	
Osteopetrosis Joint, Inflammation	2 (4%)		1 (2%)	1 (2%)	
Skeletal Muscle	(1)	(0)	(1)	(0)	
NERVOUS SYSTEM					
Brain	(50)	(50)	(50)	(50)	
Hemorrhage Hydrocephalus	1 (2%) 17 (34%)	14 (28%)	14 (28%)	14 (28%)	
Hippocampus, Necrosis			1 (2%)		
Hypothalamus, Compression Thalamus, Necrosis	17 (34%)	8 (16%)	12 (24%) 1 (2%)	14 (28%)	
Spinal Cord	(1)	(1)	(0)	(0)	
	. ,	. ,			
RESPIRATORY SYSTEM					
Lung	(50)	(50)	(50)	(50)	
Congestion Inflammation	17 (34%)	1 (2%) 22 (44%)	20 (40%)	16 (32%)	
Metaplasia, Osseous	1 (2%)	22 (4470)	20 (4070)	10 (3270)	
Alveolar Epithelium, Hyperplasia	7 (14%)	12 (24%)	9 (18%)	8 (16%)	
Artery, Hyperplasia Nose	(50)	1 (2%) (49)	(50)	(49)	
Foreign Body	7 (14%)	12 (24%)	4 (8%)	5 (10%)	
Inflammation	27 (54%)	32 (65%)	22 (44%)	18 (37%)	
Polyp, Inflammatory	1 (2%)	4 (001)	0 ( 10 ( )	4 (00()	
Glands, Cyst Olfactory Epithelium, Accumulation, Hyaline	1 (2%)	1 (2%) 2 (4%)	2 (4%)	1 (2%)	
Droplet	I (∠70)	∠ (470)			
Olfactory Epithelium, Degeneration	5 (10%)	17 (35%)	30 (60%)	48 (98%)	
Olfactory Epithelium, Metaplasia, Respiratory	9 (18%)	9 (18%)	3 (6%)	4 (8%)	

# Test Type: CHRONIC Route: SKIN APPLICATION

Species/Strain: RATS/F 344

# P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

bis(2-Chloroethoxy)methane

### CAS Number: 111-91-1

Date Report Reqsted: 11/12/2007 Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	75 MG/KG	150 MG/KG	300 MG/KG	
Olfactory Epithelium, Metaplasia, Squamous Trachea Inflammation	1 (2%) (50) 1 (2%)	(50)	(50) 3 (6%)	(50)	
SPECIAL SENSES SYSTEM					
Eye Cataract Retina, Atrophy Sclera, Metaplasia, Osseous Harderian Gland Atrophy	(50) 2 (4%) 2 (4%) 38 (76%) (50)	(50) 1 (2%) 1 (2%) 35 (70%) (50)	(50) 28 (56%) (50) 1 (2%)	(50) 2 (4%) 2 (4%) 32 (64%) (50) 2 (4%)	
Hyperplasia Inflammation Pigmentation, Porphyrin Zymbal's Gland	3 (6%) 1 (2%) (1)	1 (2%) 3 (6%) (0)	2 (4%) (0)	1 (2%) 1 (2%) (1)	
JRINARY SYSTEM					
Kidney Fibrosis Infarct	(50)	(50) 1 (2%)	(50)	(50) 1 (2%)	
Inflammation Nephropathy Renal Tubule, Cyst	47 (94%)	48 (96%) 1 (2%)	43 (86%)	1 (2%) 48 (96%)	
Renal Tubule, Hyperplasia Renal Tubule, Pigmentation, Lipofuscin Urinary Bladder Inflammation	1 (2%) (50)	(50)	(50)	1 (2%) (50) 2 (4%)	
Muscularis, Mineralization Transitional Epithelium, Hyperplasia	1 (2%)	1 (2%)	1 (2%)	1 (2%)	

# \*\*\* END OF MALE \*\*\*

TDMS No. 99028 - 05 Test Type: CHRONIC Route: SKIN APPLICATION

Species/Strain: RATS/F 344

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Date Report Reqsted: 11/12/2007 Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	75 MG/KG	150 MG/KG	300 MG/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths Moribund Sacrifice	19	18	15	19
Natural Death	19	2	7	13
Survivors				-
Terminal Sacrifice	19	30	28	18
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Esophagus	(50)	(50)	(50)	(50)
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Intestine Large, Colon	(50)	(50)	(50)	(50)
Parasite Metazoan	3 (6%)	3 (6%)	2 (4%)	1 (2%)
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Parasite Metazoan		4 (8%)	6 (12%)	5 (10%)
Ulcer	1 (2%)			
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Ulcer	1 (2%)	(50)	(50)	(50)
Liver	(50)	(50)	(50)	(50)
Angiectasis	4 (8%)	5 (10%)	1 (2%)	2 (4%)
Basophilic Focus	41 (82%)	48 (96%)	42 (84%)	30 (60%)
Clear Cell Focus	9 (18%)	9 (18%)	10 (20%)	5 (10%)
Degeneration, Cystic Eosinophilic Focus	5 (10%)	2 (4%)	6 (129/)	6 (120/)
Fatty Change	5 (10%) 9 (18%)	8 (16%) 9 (18%)	6 (12%) 4 (8%)	6 (12%) 9 (18%)
Fibrosis	9 (18%) 5 (10%)	3 (6%)	4 (8%) 10 (20%)	9 (18%) 2 (4%)
Hepatodiaphragmatic Nodule	5 (10%) 7 (14%)	3 (6%) 6 (12%)	8 (16%)	2 (4%) 8 (16%)
Inflammation	40 (80%)	45 (90%)	39 (78%)	33 (66%)
Mixed Cell Focus	40 (80%)	10 (20%)	10 (20%)	3 (6%)
Necrosis	2 (4%)	1 (2%)	2 (4%)	1 (2%)
Bile Duct, Cyst	2 (770)	1 (2%)	1 (2%)	1 (270)
Bile Duct, Hyperplasia	17 (34%)	18 (36%)	19 (38%)	12 (24%)
Centrilobular, Necrosis	4 (8%)	3 (6%)	5 (10%)	5 (10%)
Periportal, Cytoplasmic Alteration	1 (2%)	- (2/0)	- (	- ( - 0 / 0)
Mesentery	(13)	(13)	(17)	(6)
Necrosis	1 (8%)			
Fat, Necrosis	13 (100%)	12 (92%)	17 (100%)	6 (100%)
Oral Mucosa	(1)	(0)	(0)	(0)
Pancreas	(50)	(50)	(50)	(50)
Hyperplasia		1 (2%)		

# Test Type: CHRONIC Route: SKIN APPLICATION

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Date Report Reqsted: 11/12/2007 Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	75 MG/KG	150 MG/KG	300 MG/KG	
Inflammation	2 (4%)			1 (2%)	
Acinus, Atrophy	13 (26%)	12 (24%)	9 (18%)	6 (12%)	
Acinus, Hyperplasia	1 (2%)		. ,		
Duct, Cyst Stomach, Forestomach	4 (8%) (50)	6 (12%) (50)	1 (2%) (50)	2 (4%) (50)	
Inflammation	6 (12%)	3 (6%)	1 (2%)	2 (4%)	
Ulcer	4 (8%)	3 (6%)		1 (2%)	
Epithelium, Hyperplasia Stomach, Glandular	1 (2%) (50)	2 (4%) (50)	(50)	(50)	
Fibrosis	(50)	(50)	(50)	1 (2%)	
Inflammation	2 (4%)			1 (2%)	
Mineralization Ulcer	1 (2%)	1 (2%)		2 (4%) 2 (4%)	
Tongue	(0)	(0)	(0)	(1)	
ARDIOVASCULAR SYSTEM					
Heart	(50)	(50)	(50)	(50)	
Cardiomyopathy	40 (80%)	45 (90%)	42 (84%)	46 (92%)	
Fibrosis	50 (100%)	50 (100%)	50 (100%)	50 (100%)	
Thrombosis Coronary Artery, Inflammation	1 (2%) 1 (2%)	1 (2%)			
Myocardium, Infiltration Cellular, Mononuclear	50 (100%)	50 (100%)	50 (100%)	50 (100%)	
Cell					
Myocardium, Necrosis Myocardium, Vacuolization Cytoplasmic	50 (100%) 50 (100%)	50 (100%) 50 (100%)	50 (100%) 50 (100%)	50 (100%) 50 (100%)	
NDOCRINE SYSTEM					
Adrenal Cortex	(50)	(50)	(50)	(50)	
Angiectasis	1 (2%)			1 (2%)	
Hemorrhage Hyperplasia	11 (22%)	26 (52%)	18 (36%)	2 (4%) 14 (28%)	
Necrosis				7 (14%)	
Vacuolization Cytoplasmic	15 (30%)	17 (34%)	21 (42%)	15 (30%)	
Adrenal Medulla Hyperplasia	(50) 1 (2%)	(50) 3 (6%)	(50) 3 (6%)	(50) 4 (8%)	
Necrosis			1 (2%)		
Islets, Pancreatic Hyperplasia	(50) 10 (20%)	(50) 6 (12%)	(50) 5 (10%)	(50) 6 (12%)	
Parathyroid Gland	(43)	6 (12%) (46)	5 (10%) (48)	(50)	
Pituitary Gland	(50)	(50)	(50)	(50)	
Angiectasis	32 (64%)	39 (78%)	32 (64%)	26 (52%)	
Atrophy	1 (2%)				

## Test Type: CHRONIC Route: SKIN APPLICATION

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Date Report Regsted: 11/12/2007 Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	75 MG/KG	150 MG/KG	300 MG/KG	
Cyst Hemorrhage	16 (32%)	21 (42%)	17 (34%)	18 (36%) 1 (2%)	
Pars Distalis, Hyperplasia Pars Intermedia, Hyperplasia	16 (32%) 1 (2%)	26 (52%)	19 (38%)	18 (36%)	
Thyroid Gland Atrophy Cyst	(50)	(50)	(50) 1 (2%) 1 (2%)	(50)	
C-cell, Hyperplasia Follicle, Hyperplasia	33 (66%)	38 (76%) 2 (4%)	34 (68%) 3 (6%)	19 (38%)	
GENERAL BODY SYSTEM					
None					
GENITAL SYSTEM					
Clitoral Gland	(50) 1 (2%)	(50) 2 (4%)	(50) 2 (4%)	(50)	
Cyst Hyperplasia	2 (4%)	6 (12%)	6 (12%)	3 (6%)	
Inflammation	32 (64%)	32 (64%)	40 (80%)	23 (46%)	
Ovary	(50)	(50)	(50)	(50)	
Atrophy Cyst	5 (10%)	2 (4%) 4 (8%)	2 (4%) 7 (14%)	5 (10%)	
Bilatoral Cyat	0 (1070)	. (0,0)	1 (29/)		

1 (2%) (50)

4 (8%)

(0)

(50)

5 (10%)

(1)

(50)

1 (2%)

4 (8%)

(0)

HEMATOP	v eve	
	010	

Inflammation, Suppurative Cervix, Endometrium, Hyperplasia

Cervix, Myometrium, Hyperplasia

Endometrium, Hyperplasia, Cystic

Atrophy

Uterus

Vagina

Bilateral, Cyst

Bone Marrow	(50)	(50)	(50)	(49)	
Atrophy	2 (4%)				
Hyperplasia	3 (6%)	1 (2%)	2 (4%)	3 (6%)	
Lymph Node	(3)	(1)	(5)	(1)	
Deep Cervical, Hyperplasia, Lymphoid			1 (20%)		
Mediastinal, Ectasia		1 (100%)			
Mediastinal, Hyperplasia, Lymphoid	1 (33%)				
Pancreatic, Ectasia	1 (33%)				
Pancreatic, Hyperplasia, Lymphoid	1 (33%)				

(50)

1 (2%) 1 (2%)

1 (2%)

6 (12%)

(0)

# Test Type: CHRONIC Route: SKIN APPLICATION

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

bis(2-Chloroethoxy)methane

### CAS Number: 111-91-1

Date Report Reqsted: 11/12/2007 Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	75 MG/KG	150 MG/KG	300 MG/KG		
Lymph Node, Mesenteric	(50)	(50)	(50)	(50)		
Hyperplasia, Lymphoid	1 (2%)					
Spleen	(50)	(50)	(50)	(50)		
Atrophy	3 (6%)			2 (4%)		
Fibrosis Hematopoietic Cell Proliferation	29 (58%)	37 (74%)	34 (68%)	1 (2%) 26 (52%)		
Infarct	29 (30 %)	57 (1470)	34 (00 %)	1 (2%)		
Thymus	(49)	(50)	(50)	(49)		
Átrophy	43 (88%)	50 (10Ó%)	47 (94%)	35 (71%)		
Hemorrhage				1 (2%)		
ITEGUMENTARY SYSTEM						
Mammary Gland	(50)	(50)	(50)	(50)		
Hyperplasia Inflammation	5 (10%)		3 (6%)	2 (4%)		
Skin	1 (2%) (50)	(50)	(50)	(49)		
Cyst Epithelial Inclusion	(30)	(50)	1 (2%)	(43)		
Control Dermis, Inflammation	1 (2%)		1 (273)			
Control Epidermis, Hyperplasia	1 (2%)					
Dermis, Inflammation		1 (2%)	1 (2%)			
Epidermis, Hyperplasia		1 (2%)				
Epidermis, Ulcer		1 (2%)	1 (2%)			
Sebaceous Gland, Hyperplasia	0 (00()		1 (2%)	4 (22()		
Site Of Application - Dermis, Fibrosis	3 (6%)	2(40())	1 (2%)	1 (2%)		
Site Of Application - Dermis, Inflammation Site Of Application - Epidermis,		2 (4%)	3 (6%)	2 (4%)		
Hyperkeratosis			1 (2%)			
Site Of Application - Epidermis, Hyperplasia	1 (2%)	2 (4%)	5 (10%)	1 (2%)		
Site Of Application - Epidermis, Ulcer	1 (2%)	1 (2%)	3 (6%)	1 (2%)		
Subcutaneous Tissue, Necrosis	. (=)		1 (2%)			
USCULOSKELETAL SYSTEM						
Bone	(50)	(50)	(50)	(50)		
Joint, Inflammation	1 (2%)			3 (6%)		
ERVOUS SYSTEM						
Brain	(50)	(50)	(50)	(50)		
Hemorrhage	1 (2%)	4.4 (000()	0 (400/)	F (100()		
Hydrocephalus Hippocampus, Necrosis	11 (22%)	14 (28%) 1 (2%)	8 (16%)	5 (10%)		
rippocampus, mecrosis		I (∠70)				

# Test Type: CHRONIC Route: SKIN APPLICATION

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Date Report Reqsted: 11/12/2007 Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	75 MG/KG	150 MG/KG	300 MG/KG	
Hypothalamus, Compression Vein, Infiltration Cellular, Mononuclear Cell	13 (26%)	12 (24%) 1 (2%)	8 (16%)	5 (10%)	
ESPIRATORY SYSTEM					
Lung	(50)	(50)	(50)	(50)	
Congestion Inflammation	1 (2%) 18 (36%)	31 (62%)	2 (4%) 24 (48%)	1 (2%) 19 (38%)	
Metaplasia, Osseous			1 (2%)		
Thrombosis Alveolar Epithelium, Hyperplasia	1 (2%) 1 (2%)	7 (14%)	7 (14%)	6 (12%)	
Alveolar Epithelium, Metaplasia, Squamous	1 (270)	7 (14%)	3 (6%)	0 (12%)	
Bronchus, Hyperplasia	(10)	1 (2%)			
Nose Foreign Body	(49) 1 (2%)	(49) 2 (4%)	(50) 2 (4%)	(49)	
Inflammation	10 (20%)	14 (29%)	16 (32%)	6 (12%)	
Glands, Cyst		4 (00()	4 (00()	1 (2%)	
Olfactory Epithelium, Accumulation, Hyaline Droplet		1 (2%)	1 (2%)		
Olfactory Epithelium, Degeneration	5 (10%)	4 (8%)	18 (36%)	49 (100%)	
Olfactory Epithelium, Metaplasia, Respiratory Olfactory Epithelium, Metaplasia, Squamous			1 (2%)	1 (2%) 1 (2%)	
Respiratory Epithelium, Degeneration			1 (2%)		
Trachea	(50)	(50)	(50)	(50)	
Glands, Cyst		1 (2%)			
PECIAL SENSES SYSTEM					
Eye	(50)	(50)	(50)	(50)	
Cataract	1 (2%)	2 (4%)	3 (6%)	5 (10%)	
Retina, Atrophy Sclera, Metaplasia, Osseous	2 (4%) 7 (14%)	3 (6%) 2 (4%)	4 (8%) 6 (12%)	5 (10%) 4 (8%)	
Harderian Gland	(50)	(50)	(50)	(50)	
Hyperplasia			1 (2%)		
Inflammation	5 (10%)	11 (22%)	9 (18%)	10 (20%)	
Capillary, Hyperplasia Lacrimal Gland	(0)	1 (2%)	(0)	(0)	
Hyperplasia		1 (100%)			
Zymbal's Gland	(0)	(0)	(0)	(1)	
IRINARY SYSTEM					
Kidney	(50)	(50)	(50)	(50)	
i danoj	(00)	(00)	(00)	(00)	

# Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: RATS/F 344

### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Date Report Reqsted: 11/12/2007 Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	75 MG/KG	150 MG/KG	300 MG/KG
Hydronephrosis	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Inflammation, Suppurative Nephropathy Renal Tubule, Cyst	30 (60%) 1 (2%)	1 (2%) 30 (60%)	34 (68%)	25 (50%)
Urinary Bladder Inflammation	(50) 1 (2%)	(50)	(49)	(50)
Transitional Epithelium, Hyperplasia	1 (270)		1 (2%)	

\*\*\* END OF REPORT \*\*\*